

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**国药集团**  
SINOPHARM

**CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED**  
**中國中藥控股有限公司**

*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 570)**

**ANNOUNCEMENT**  
**PURSUANT TO RULE 13.09 OF THE LISTING RULES**  
**AND**  
**THE INSIDE INFORMATION PROVISIONS UNDER PART XIVA OF**  
**THE SECURITIES AND FUTURES ORDINANCE**

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) has noted certain news reports dated 7 December 2022 and received relevant enquiries regarding a potential proposal by China National Pharmaceutical Group Co., Ltd. (中國醫藥集團有限公司) (“**CNPGC**”), the indirect parent company of Sinopharm Group Hongkong Co., Limited (“**Sinopharm Hongkong**”), which is the controlling shareholder of the Company, to privatise the Company. Having made such enquiry as is reasonable in the circumstances with Sinopharm Hongkong, the Company has been informed by Sinopharm Hongkong that as of the date of this announcement, CNPGC, after its preliminary consideration, would not proceed with the proposal to privatise the Company.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and/or other securities of the Company.**

By order of the Board  
**China Traditional Chinese Medicine Holdings Co. Limited**  
**CHEN Yinglong**  
*Chairman*

Hong Kong, 8 December 2022

*As at the date of this announcement, the Board comprises twelve Directors, of which Mr. CHEN Yinglong, Mr. CHENG Xueren and Mr. YANG Wenming are executive Directors; Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.*